Efficacy of tgrx-678, a potent BCR::ABL1 allosteric inhibitor, in CML-CP and CML-AP patients harboring T315I mutation: Results from a phase 1 study
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Qian Jiang, Weiming Li, Yanli Zhang, Qiang WANG, Suning Chen, Bingcheng LIU, Jie Jin, Zhenfang Liu, Zhuogang Liu, Jianyu Weng, Xin Du, Xielan Zhao, Li Meng, Shujie Yan, xiaomeng Dong, Yihan Wang, Jingrong Cao
Institutions: Peking University, Wuhan Union Hospital, Huazhong University of Science and Technology, Henan Cancer Hospital, Nanfang Hospital, Southern Medical University, First Affiliated Hospital of Soochow University, Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Hematology & Blood Diseases Hospital, State Key Laboratory of Experimental Hematology, First Affiliated Hospital Zhejiang University, Guangxi Medical University, First Affiliated Hospital of GuangXi Medical University, China Medical University, Guangdong Provincial People's Hospital, Shenzhen University, Shenzhen Second People's Hospital, Central South University, Xiangya Hospital Central South University, Tongji Hospital
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417020841
Cites:
Cited by:
Related to: